Bulbul Bahuguna, MD
Psychiatry · Deerfield, ILNPI 1912981366
Payments from drug & device makers
Across 112 payments — averaging $32.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$932
- Otsuka America Pharmaceutical, Inc.$672
- Ironshore Pharmaceuticals Inc.$310
- Takeda Pharmaceuticals U.S.A., Inc.$289
- Lundbeck LLC$268
- Johnson & Johnson$248
- plus $916 from 7 others
What the payments were for
- Food & beverage$3,634100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 30 | $932 |
| Otsuka America Pharmaceutical, Inc. | 17 | $672 |
| Ironshore Pharmaceuticals Inc. | 7 | $310 |
| Takeda Pharmaceuticals U.S.A., Inc. | 13 | $289 |
| Lundbeck LLC | 16 | $268 |
| Johnson & Johnson | 10 | $248 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $229 |
| Neurocrine Biosciences, Inc. | 4 | $181 |
| Sunovion Pharmaceuticals Inc. | 3 | $154 |
| Gilead | 1 | $110 |
| Teva Pharmaceuticals USA, Inc. | 1 | $102 |
| Bausch Health US, LLC | 5 | $81 |
| Shire North American Group Inc | 3 | $59 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VRAYLAR$481
- REXULTI$243
- CAPLYTA$229
- JORNAY PM$124
- INGREZZA$121
- ABILIFY MAINTENA$121
- Jornay PM 20mg capsules (Bottle of 100)$116
- LATUDA$111
- Trodelvy$110
- TRINTELLIX$103
- AUSTEDO$102
- SPRAVATO$101
How this compares
$3,634 in reported general payments places this provider in the 85th percentile of 1,344 psychiatry providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Quetiapine Fumarate ErQuetiapine Fumarate | 21 | $3,515 |
| Aripiprazole | 52 | $2,575 |
| Bupropion XlBupropion Hcl | 55 | $1,752 |
| Quetiapine Fumarate | 44 | $1,610 |
| Clonazepam | 79 | $1,587 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 53 | $1,440 |
| Escitalopram Oxalate | 74 | $1,358 |
| Trazodone Hcl | 102 | $1,260 |
| Protriptyline Hcl | 11 | $1,174 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 54 | $965 |
| Duloxetine Hcl | 46 | $901 |
| Olanzapine | 16 | $854 |
| Sertraline Hcl | 44 | $788 |
| Imipramine Hcl | 11 | $599 |
| Lamotrigine | 36 | $501 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in Deerfield
- Jeffrey RossNorthbrook$10.8M
- Yuhwen ChowChicago$8.5M
- Mark LermanNorthbrook$4.5M
- Danesh AlamWinfield$2.7M
- John ZajeckaSkokie$2.5M
- Riaz BaberNaperville$2.4M
- Michael GreenbaumLibertyville$2.2M
- Sandeep GaonkarNaperville$1.8M
- Jon GrantChicago$1.4M
- David KempOak Lawn$1.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.